Publicação: VNTR Polymorphism in Intron 4 of the eNOS Gene and the Risk of Gastrointestinal Bleeding: A Case-control Study
dc.contributor.author | Forgerini, Marcela [UNESP] | |
dc.contributor.author | Urbano, Gustavo | |
dc.contributor.author | de Nadai, Tales Rubens | |
dc.contributor.author | Zanelli, Cleslei Fernando [UNESP] | |
dc.contributor.author | Valentini, Sandro Roberto [UNESP] | |
dc.contributor.author | Mastroianni, Patrícia de Carvalho [UNESP] | |
dc.contributor.institution | Universidade Estadual Paulista (UNESP) | |
dc.contributor.institution | Universidade de São Paulo (USP) | |
dc.date.accessioned | 2023-03-01T20:49:45Z | |
dc.date.available | 2023-03-01T20:49:45Z | |
dc.date.issued | 2022-06-01 | |
dc.description.abstract | Background & Aims: Considering the lack of knowledge regarding the influence of the variable number of repeats of 27 pb in intron 4 (4b/4a VNTR-rs61722009) of the endothelial nitric oxide synthase (eNOS) on the drug response, we assessed the influence of this polymorphism for the risk of upper gastrointestinal bleeding (UGIB). Methods: A case-control study, including 200 cases and 706 controls, was conducted in a Brazilian hospital complex. Cases were participants with UGIB diagnosis. Controls were participants admitted to surgical procedures not related to gastrointestinal problems. The 4b/4a VNTR was determined through polymerase chain reaction followed by fragment analysis. Conditional logistic regression models were designed. The additive interaction between the presence of the 4b/4a VNTR variant and the use of low-dose aspirin (LDA) and nonsteroidal anti-inflammatory drugs (NSAIDs) was calculated by fitting the Cox regression model through the parameters of Synergism index (S) and Relative Excess Risk Due To Interaction (RERI). Results: The presence of the 4b/4a VNTR variant did not increase the risk of UGIB: carriers of the 4a/4a genotype (OR=0.37, 95%CI: 0.09-1.45) and of the variant allele “4a” (OR=0.91, 95%CI: 0.55-1.51). The risk of UGIB in LDA users carriers of the wild genotype (OR=4.96, 95%CI: 2.04-2.06) and the variant allele “4a” (OR=3.49, 95%CI: 1.18-10.38) is similar, as well as for NSAID users carriers of the wild genotype (OR=5.73, 95%CI: 2.61-12.60) and variant allele “4a” (OR=5.51, 95%CI: 1.42-15.82). No additive interaction was identified between the presence of the genetic variant and the use of LDA [RERI:-1.44 (95%CI:-6.02–3.14; S: 0.63 (95%CI:-1.97–1.15)] and NSAIDs [RERI:-0.13 (95%CI:-6.79–6.53; S: 0.97 (95%CI:-0.23–4.19)] on the UGIB risk. Conclusion: Our data suggests that there is no increase in the magnitude of UGIB risk in LDA and NSAIDs users’ carrying the variant allele “4a”. | en |
dc.description.affiliation | Department of Drugs and Medicines School of Pharmaceutical Sciences São Paulo State University (UNESP) | |
dc.description.affiliation | Department of Surgery School of Medicine University of São Paulo | |
dc.description.affiliation | Department of Public Health Bauru School of Dentistry University of São Paulo (USP) | |
dc.description.affiliation | Department of Biological Sciences School of Pharmaceutical Sciences São Paulo State University (UNESP) | |
dc.description.affiliationUnesp | Department of Drugs and Medicines School of Pharmaceutical Sciences São Paulo State University (UNESP) | |
dc.description.affiliationUnesp | Department of Biological Sciences School of Pharmaceutical Sciences São Paulo State University (UNESP) | |
dc.description.sponsorship | Universidade Estadual Paulista | |
dc.description.sponsorship | Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) | |
dc.description.sponsorship | Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) | |
dc.description.sponsorship | Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) | |
dc.description.sponsorshipId | CAPES: 001 | |
dc.description.sponsorshipId | FAPESP: 2017/24193-3 | |
dc.description.sponsorshipId | FAPESP: 2018/07501-9 | |
dc.description.sponsorshipId | CNPq: 401060/2014-4 | |
dc.format.extent | 176-183 | |
dc.identifier | http://dx.doi.org/10.15403/JGLD-4226 | |
dc.identifier.citation | Journal of Gastrointestinal and Liver Diseases, v. 31, n. 2, p. 176-183, 2022. | |
dc.identifier.doi | 10.15403/JGLD-4226 | |
dc.identifier.issn | 1841-8724 | |
dc.identifier.scopus | 2-s2.0-85131903635 | |
dc.identifier.uri | http://hdl.handle.net/11449/241162 | |
dc.language.iso | eng | |
dc.relation.ispartof | Journal of Gastrointestinal and Liver Diseases | |
dc.source | Scopus | |
dc.subject | aspirin | |
dc.subject | gastrointestinal bleeding | |
dc.subject | nonsteroidal anti-inflammatory drugs | |
dc.subject | NSAIDs | |
dc.subject | peptic ulcer hemorrhage | |
dc.subject | tandem repeat sequences | |
dc.subject | UGIB | |
dc.subject | VNTR Sequences | |
dc.title | VNTR Polymorphism in Intron 4 of the eNOS Gene and the Risk of Gastrointestinal Bleeding: A Case-control Study | en |
dc.type | Artigo | pt |
dspace.entity.type | Publication | |
relation.isDepartmentOfPublication | 5004bcab-94af-4939-b980-091ae9d0a19e | |
relation.isDepartmentOfPublication | e214da1b-9929-4ae9-b8fd-655e9bfeda4b | |
relation.isDepartmentOfPublication.latestForDiscovery | 5004bcab-94af-4939-b980-091ae9d0a19e | |
unesp.department | Ciências Biológicas - FCF | pt |
unesp.department | Fármacos e Medicamentos - FCF | pt |